In QWINT-2, efsitora helped adults naïve to insulin therapy currently using and not using GLP-1 receptor agonists achieve an A1C below 7% Detailed results were published in The New England Journal of Medicine and simultaneously […]
Tag: Eli Lilly and Company
In a first-of-its-kind fixed dose study, once weekly insulin efsitora alfa leads to A1C reduction similar to daily insulin
In the phase 3 study, QWINT-1, efsitora was administered via four fixed doses once weekly in a single-use autoinjector in people with type 2 diabetes using basal insulin for the first time In a second […]
Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity
Distributed through LillyDirect®‘s self-pay channel, Zepbound single-dose vials are at least 50% less than the list price of all other incretin medicines for obesity INDIANAPOLIS, Aug. 27, 2024 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today […]
Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease
Broadens Lilly’s immunology pipeline with Morphic’s oral integrin therapies, including MORF-057 Reinforces the company’s strategy of delivering potential first or best-in-class therapies in the field of gastroenterology INDIANAPOLIS, Aug. 16, 2024 /PRNewswire/ — Eli Lilly […]
Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 Billion
Revenue in Q2 2024 increased 36%, driven by Mounjaro, Zepbound and Verzenio. When excluding $579.0 million of revenue from the sale of rights for Baqsimi in Q2 2023, revenue in Q2 2024 increased 46%. Excluding […]
